COMPANY PRESENTATION February 2016 NASDAQ: KMDA Company Snapshot - - PowerPoint PPT Presentation

COMPANY PRESENTATION

February 2016 NASDAQ: KMDA

Fully integrated, international (NASDAQ-traded) biopharmaceutical company Diversified portfolio with

• ver 20 specialty products.

Focused on Respiratory,

• rphan diseases and

plasma derived therapeutics Global leader for Alpha-1 Antitrypsin (AAT) Exclusive distributer of leading biopharmaceutical companies with significant market share ( > 50%). Strategic partnerships with industry leaders (Inc. Baxalta, Biotest, Kedrion, Chiesi)

Company Snapshot

Mission

3

Development, production and marketing

• f specialty, life-saving pharmaceuticals

Unique Product Line Strategic Partnerships Significant Market Share

Strategy

Media Coverage

4

Kamada and Baxter Enter into a Strategic Agreement for the Distribution and Manufacture

• f Intravenous Liquid AAT to

Treat Alpha-1 Antitrypsin Deficiency in the US

24 Aug. 2010

Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease

2 Feb. 2015

Kamada Reports Encouraging Interim Data from its Phase 1/2 Extension Study: AAT in pediatric patients with Type 1 Diabetes

Bloomberg

11 Dec. 2014 Kamada Ltd Announces New Exclusive Distribution Agreement with Chiesi Farmaceutici 4 Aug. 2012

NASDAQ Welcomes Kamada Ltd. [KMDA] to The NASDAQ Stock Market

31 May. 2013

Kamada Announces Completion

• f Pivotal Phase ll/lll Clinical

Trial in Europe and Canada of inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

11 Dec. 2013

Multi-National Sales Platform

5

Additional 10 countries in registration

Key Strategic Alliances

Diversified Product Portfolio

7

RESPIRATORY ANTIBODIES (various expertise) Anti-rabies immunoglobulin (human) Rho(D) immunoglobulin (human) Rho(D) immunoglobulin (human) Gamma globulins (IgG) (human) Varicella zoster immunoglobulin Hepatitis B immunoglobulin (human) Hepatitis B immunoglobulin (human) CMV immunoglobulin (human) Anti-snake venom CRITICAL AND HOSPITAL CARE Heparin sodium 5,000 IU/ml Human serum Albumin Heparin sodium Bupivacaine HCl HAEMOPHILIA Coagulation Factor VIII (human) Coagulation Factor IX (human) Alpha-1 Antitrypsin I.V (human) Tobramycin Inhaled Beclomethasone+Formoterol

Clinical Pipeline Focused on Orphan Indications

Product Indication Phase I Phase II Phase III Market Partner Intravenous AAT AAT Deficiency U.S. D1-AAT (IV) Type 1 Diabetes* U.S. G1-AAT (IV) GVHD* U.S. L1-AAT (IV) Lung Transplant U.S. Inhaled AAT AAT Deficiency* B1-AAT (IH) Bronchiectasis* C1-AAT (IH) Cystic Fibrosis* KamRAB (IM) Prophylaxis for Rabies U.S.

U.S: Phase III Completed (LPO) Ph II/III In Process FDA Approved (2010) Completed Ph I/II In Process U.S.: IND Approved U.S.: Ph II In Process EU: Completed Completed Completed

* Orphan Drug Designation IV= intravenous IH= inhaled

Ph I/II in Initiation

EU

cGMP standard, one stop shop: registration, regulation support, importation, distribution, storage, marketing, pharmacovigilance, clinical trials and QA, QC. Long term experience in development and marketing of specialty Rx pharmaceuticals. Excellent relationships with key personnel at the Israeli MOH and HMOs (management, decision makers, medical department and purchase department).

Our Israeli Sales & Marketing Strengths & Capabilities

9

Vast experience in various medical fields: Respiratory, Allergy & Immunology, Hematology, Infectious diseases, Neurology, Critical care, Gastroenterology & Liver diseases, Fertility and more. Proven multinational sales capabilities through long-term connection with local distributors in Latin America, CIS & Asia. FDA approved, State of the art production facility. More than 50% market share in key in-licensed products.

Kamada’s success and market share growth is achieved through a collaboration with KOLs and the establishment of a leading premium brand.

• A seasoned team of medical reps covering all hospitals and most primary-care clinics.
• On going personal contact with KOLs and physicians.
• Local adaptations of all marketing aids: leaflets, brochures, scientific articles, etc.
• Sponsorship of relevant medical conferences & seminars.
• Strong marketing intelligence capabilities.
• Advanced digital marketing capabilities.
• In-house medical director support.

Dedicated to Create a Leading Brand

10

Market research & analysis, including detailed business plan.

Expertise in Market Development of Orphan Indications

11

Raising disease awareness & patients diagnosis, through effective diagnosis programs. Collaboration with KOLs and dedicated treatment centers. Patients and physicians organizations support, Development of patients support programs. Experience in Named-Patient-Basis sales, prior to registration.

• Regulatory Capabilities:
• In-house, experienced dedicated regulatory affairs department.
• Proven record in submission and approvals to the National health basket.
• Pharmacovigilance (in cooperation with QA and Clinical).
• Logistic Capabilities:
• In-house storage (fully cGMP and FDA approved).
• Extensive cold-chain expertise.
• Advanced nation-wide cGDP-approved delivery platform.
• Home care experience and capabilities.
• Dedicated account management & customer service.

One-Stop-Shop Services

12

• The national leader in logistics for the pharmaceutical industry, with Cutting edge facility

for the storage and distribution of pharmaceutical products

• Serves more than 1,200 delivery points throughout Israel
• Immediate life saving deliveries 24/7

Novolog: Our Logistic Partner

13

14 A one- stop- shop strategic partner In-house seasoned sales & marketing team Multinational capabilities and strong financial positioning Unique expertise through the entire supply chain of specialty life- saving pharmaceuticals

Why Partner with Kamada

www.kamada.com

THANK YOU

Hanni Neheman | Director Sales & Marketing | hannin@kamada.com

15